



Depression in Dementia: Challenges in Diagnosis and Management

BrainXchange Webinar

October 12, 2015

Dr. Dallas Seitz MD PhD FRCPC

Dr. Julia Kirkham MD FRCPC

Department of Psychiatry, Queen's University

Providence
Care



Disclosures

- Dr. Seitz
 - Advisory Board: Eli-Lilly (2013)
 - Research Grants: CIHR, Alzheimer’s Association, SEAMO AFP Innovation Fund
- Dr. Kirkham has no conflicts of interest



Objectives

- Understand the phenomenology and epidemiology of depression in dementia (DpD)
- Develop an approach to screening for and diagnosis of DpD
- Review the evidence for the treatment of DpD
- Discuss resources in Ontario for managing depressed older adults with dementia



Depression in Dementia

- Among the non-cognitive symptoms of dementia
- Behavioral and Psychological Symptoms of Dementia (BPSD), neuropsychiatric symptoms (NPS), responsive behaviors

International Psychogeriatrics Association (1996):

“Signs and symptoms of disturbed perception, thought content, mood, or behavior that frequently occur in patients with dementia”¹

1. Finkel, Int Psychogeriatr, 1996; 8(suppl 3):497-500



Depression in Dementia

- Depression is risk factor for development of Alzheimer's disease¹ and individuals with dementia are at higher risk for depression
 - Early-life depression → 2x increased risk for late-life dementia²
 - Direction of causality?

1. Byers, Nature Rev Neurology, 2011
2. Enach, Curr Op in Psych, 2011


Prevalence of Depressive Symptoms and Major Depression in Dementia

- Wide variation in estimates
- 20-30% of people with AD have depressive symptoms¹
 - Vascular dementia and DLB 2 – 3X > Alzheimer's
- Few longitudinal studies on the course of DpD
 - Variable results


1. Enach, Curr Op in Psych, 2011

Prevalence of DpD


- Prevalence MDD in any dementia: 9.1% (8.2 to 10%)
- Alzheimer's disease: 5.1% (3.1% to 8.4%) vs. vascular dementia 15.5% (9.4% to 24.3%)



NPS in Alzheimer's Disease



Associations with Stage of Illness





Prevalence of NPS in Long-Term Care

- 60% of individuals LTC settings have dementia¹
- Overall prevalence of NPS:
 - Median prevalence of any NPS: 78%
- Prevalence of NPS²:
 - Psychosis 15 – 30%
 - Depression: 30 – 50%
 - Physical agitation: 30%
 - Aggression: 10 – 20%

1. Seitz, *Int Psychogeriatr*, 2010


2. Zuidema, *J Geriatr Psych Neurol*, 2007



Prevalence of NPS in LTC

BEHAVE – AD Items	Prevalence
Delusions	54%
Hallucinations	33%
Psychosis	60%
Aggression	77%
Activity Disturbance	53%
Diurnal Disturbance	47%
Affective Disturbance	60%
Anxiety	69%
Any BEHAVE-AD	92%

Prevalence of NPS in MCI





NPS in MCI and AD Conversion

- Depression is predictor of conversion in MCI¹
- Each symptom of anxiety in MCI increases risk of AD conversion by HR = 1.8²
 - Persistent worrying (HR = 5.3), decision making (HR = 5.6)
 - MCI Conversion over 3 years:
 - No anxiety: 40.9%
 - Anxiety: 83.3%
- MCI with apathy associated with 6.9X increased risk of conversion³

1. Gabryelewicz, Int J Geriatr Psychiatry, 2007
2. Palmer, Neurology, 2007
3. Palmer, J Alz Dis, 2010



Persistence of NPS

- Neuropsychiatric symptoms are often chronic^{1,2}
 - More likely to persist: depression, delusions, aberrant motor behavior
 - Less likely to persist: hallucinations, disinhibition

1. Steinberg, Int J Geriatr Psychiatry, 2004
2. Aalten, Int J Geriatr Psychiatry, 2005



Management

- Assessment
- Nonpharmacological
- Pharmacological



Challenges: Diagnosis of DpD

- Depression screening instruments not well validated in dementia
 - Deficits in awareness, communication skills may influence questionnaires and symptom reporting¹
- Overlap between symptoms of depression and symptoms of dementia
 - Apathy, decreased interest, fatigue
- Older adults report fewer affective symptoms²
 - “Depression without sadness”

1. Enach, Curr Op in Psych, 2011
2. Hochang, Biol Psychiatry, 2003



Diagnosing Depression in Dementia

- Similar to diagnosing depression in individuals without dementia
- Two week period of **three or more symptoms** of (one of first two required):
 - **Depressed mood**
 - **Decreased positive affect or pleasure in response to social contacts and usual activities**
 - Disruption of sleep
 - Disruption of appetite
 - Psychomotor changes
 - Irritability
 - Fatigue or loss of energy
 - Feelings of worthlessness, hopelessness, or excessive guilt
 - Recurrent thoughts of death, suicidal ideation or plan
- Criteria also met for dementia of the Alzheimer Type
- Symptoms cause distress and not caused by other conditions or substances



Measuring Depression in Dementia

- Cornell Scale for Depression in Dementia
- Based on informant interview *and* patient observation over the preceding week
- Items scored from 0=absent, 1=mild, 2=severe
- 19 items
- Items include mood-related items, behavioral changes, physical changes, activity cycle, and negative ideation

Cornell Scale for Depression in Dementia

Name _____ Age _____ Sex _____ Date _____

Inpatient Nursing Home Resident Outpatient

Scoring System

A = unable to evaluate 0 = absent 1 = mild or intermittent 2 = severe

Ratings should be based on symptoms and signs occurring during the week prior to interview. No score should be given in symptoms result from physical disability or illness.

A. Mood-Related Signs

1. Anxiety: anxious expression, ruminations, worrying	a	0	1	2
2. Sadness: sad expression, sad voice, tearfulness	a	0	1	2
3. Lack of reactivity to pleasant events	a	0	1	2
4. Irritability: easily annoyed, short-tempered	a	0	1	2

B. Behavioral Disturbance

5. Agitation: restlessness, handwringing, hairpulling	a	0	1	2
6. Retardation: slow movement, slow speech, slow reactions	a	0	1	2
7. Multiple physical complaints (score 0 if GI symptoms only)	a	0	1	2
8. Loss of interest: less involved in usual activities (score only if change occurred acutely, i.e. in less than 1 month)	a	0	1	2

C. Physical Signs

9. Appetite loss: eating less than usual	a	0	1	2
10. Weight loss (score 2 if greater than 5 lb. in 1 month)	a	0	1	2
11. Lack of energy: fatigues easily, unable to sustain activities (score only if change occurred acutely, i.e., in less than 1 month)	a	0	1	2

D. Cyclic Functions

12. Diurnal variation of mood: symptoms worse in the morning	a	0	1	2
13. Difficulty falling asleep: later than usual for this individual	a	0	1	2
14. Multiple awakenings during sleep	a	0	1	2
15. Early morning awakening: earlier than usual for this individual	a	0	1	2

E. Ideational Disturbance

16. Suicide: feels life is not worth living, has suicidal wishes, or makes suicide attempt	a	0	1	2
17. Poor self esteem: self-blame, self-depreciation, feelings of failure	a	0	1	2
18. Pessimism: anticipation of the worst	a	0	1	2
19. Mood congruent delusions: delusions of poverty, illness, or loss	a	0	1	2

CSDD Scores:

≥ 9 MDD

≥ 13 severe depression

Sensitivity: 80 – 90%

Specificity: 70 – 80%



Measuring Depression in Dementia

- Other scales:
 - Geriatric Depression Scale
 - Hamilton Rating Scale for Depression
 - Montgomery-Asberg Depression Rating Scale



Assessment

History

- Past psychiatric history
 - Depression, bipolar disorder, anxiety
 - Prior treatments
- Past Medical History:
 - Conditions that may be affected by treatments
 - Diseases that may increase risk of depression (e.g. Parkinson's disease, stroke)



Management of DpD

- Differential Diagnosis:
 - Delirium (especially hypoactive)
 - Pain or discomfort
 - Other medical causes
 - Environment causes

Assessment

Medication use potentially related to depression:

- Methyldopa
- Benzodiazepines
- Propranolol
- Reserpine
- Steroids
- Anti-Parkinsonian drugs
- β blockers
- Cimetidine
- Clonidine
- Hydralazine
- Oestrogens
- Progesterone
- Tamoxifen
- Vinblastine
- Vincristine
- Dextropropoxyphene

Medical conditions potentially related to depression:

- Endocrinopathy—hypothyroidism, hyperthyroidism, hypoparathyroidism, hyperparathyroidism, hypoadrenocorticism, hyperadrenocorticism, Cushing's disease
- Malignant disease—leukaemia, lymphoma, pancreatic cancer
- Cerebrovascular disease—lacunar infarcts, stroke, vascular dementia
- Myocardial infarction
- Metabolic disorder—B12 deficiency, malnutrition

Alexopoulos, Lancet, 2005

Nonpharmacological Interventions for NPS



- Training caregivers or staff in behavioral management strategies and communication
- Mental health consultations
- Participation in pleasant events
- Exercise
- Music
- Sensory stimulation

Cohen-Mansfield, Am J Geriatr Psychiatry, 2001

Livingston, Am J Psychiatry, 2005

Seitz, JAMDA, 2012

General Interventions for Depressive Symptoms

- Staff training approaches to improve engagement in pleasant activities
- Small RCTs of reminiscence therapy¹, validation therapy for LTC residents
- AD-Venture, wheelchair bicycling for LTC residents with dementia and depression²
- “Simple Pleasures” interventions improved affect and engagement in dementia³

1. Goldwasser, Int J Aging Hum Dev, 1987
2. Buettner L, Am J Alz Dis Other Dement, 2002
3. Buettner L, Am J Alz Dis, 1999




Interventions for Depression

- Training family caregivers in behavioral therapy in either pleasant event scheduling or problem-solving approaches reduces depression in both patients and caregivers¹
- Caregiver training in behavioral management and regular exercise (Reducing Disability in Alzheimer Disease) reduces depression and improves function

1. Teri, J Gerontol B Psychol Sci Soc Sci, 1997
2. Teri, JAMA, 2003


Psychotherapy Treatments for DpD

- 6 randomized controlled trials¹
 - Based on various models (CBT, IPT, counselling)
- Overall, psychotherapy more effective than control conditions (d=0.22, 0.03 to 0.41, P=0.02)
- No effect on secondary outcomes, such as ADLs, quality of life, cognition, or caregiver depression



Problem Solving Therapy

- PATH=problem-solving therapy approach
 - compensatory strategies, environmental adaptations, and caregiver participation
- Participants with at least mild cognitive impairment, MMSE >17
- Remission rate = 38% vs 14% vs. supportive therapy





Antidepressants for DpD

- 11 randomized controlled trials¹
- 5 positive, 6 negative studies
 - SSRIs: sertraline, citalopram, fluoxetine
 - SNRIs: venlafaxine
 - Other: mirtazapine, moclobemide, maprotiline, imipramine, clomipramine


1. Enach, Curr Op in Psych, 2011



Antidepressants for DpD

- 2 meta-analyses of antidepressants for depression in dementia failed to find statistically significant benefits over placebo:
 - Nelson et al¹ (N=7 studies):
 - Response OR: 2.12 (0.95 – 4.70)
 - Remission OR: 1.97 (0.85 – 4.55)
 - Adverse event rates relatively low: 9% vs. 6% with placebo
 - Bains et al² (N=4 studies)
 - Weak support for efficacy of antidepressants

1. Nelson, J Am Geriatr Soc, 2011
2. Bains et al., Cochrane Syst Rev, 2002



1. Nelson, J Am Geriatr Soc, 2011



HTA-SADD Study

- RCT of sertraline, mirtazapine and placebo in mild to moderate dementia (N=326)¹
- No benefit for either drug over placebo on depression outcomes, all groups improved
- Some early benefit for mirtazapine over sertraline on behavioral symptoms and caregiver quality of life
- Higher adverse event rates for sertraline (GI) and mirtazapine (drowsiness) compared to placebo

1. Banerjee, Lancet, 2011



Discontinuing Antidepressants

- RCT of antidepressant discontinuation in LTC residents without major depression in Norway (N=128)
- Increase in depressive symptoms at week 25
 - 2 point difference on CSDD (6 vs 4, $p = 0.04$)
 - > 30% deterioration in CSDD: 54% discontinuation vs. 29% continued, $P = 0.006$
 - Less severe baseline depressive symptoms associated with greatest deterioration



Antidepressants for Other NPS

- SSRIs have some benefits in treating agitation, psychosis and other NPS¹ (N=7)
- Citalopram more effective than placebo in reducing NPS²
 - Doses of 20 – 30 mg daily (Note: FDA warning about citalopram doses above 20 mg daily)
- Sertraline had modest effect on agitation compared to placebo³
 - Doses 25 – 100 mg daily

1. Seitz, Cochrane Data Syst Rev, 2011
2. Pollock, Am J Psychiatry, 2002
3. Finkel, Int J Geriatr Psychiatry, 2004



Selective Serotonin Reuptake Inhibitors

- No significant difference noted between SSRIs and typical antipsychotics¹ or citalopram compared to risperidone² on NPS
- Similar results found for escitalopram (10 mg daily) compared to risperidone³

1. Seitz, Cochrane Database Syst Rev, 2011
2. Pollock, Am J Geriatr Psychiatry, 2007
3. Barak, Int Psychogeriatric, 2011




Citalopram for Agitation: CITAD

- RCT of citalopram (10 – 30 mg daily) or placebo for AD patient with significant agitation
 - Majority received 30 mg of citalopram*
- Significant improvements on NBRS-A, CMAI with citalopram compared to placebo
- 40% of citalopram vs 26% of individuals with placebo had moderate or marked improvement
- Worsening of cognition noted with citalopram



Future Directions

- Additional studies of psychotherapy and non-pharmacological treatments for DpD
- Further evaluation of pharmacological treatments for DpD
- ***Optimizing detection of DpD in routine clinical practice using depression rating scales***



Depression rating scales for diagnosis of depression in older adults with Alzheimer's disease or related dementia (Protocol)

Seitz DP, Quinn TJ, Takwoingi Y, Gill SS, Lanctôt KL, Herrmann N, Rochon P, Kirkham JG, Rapoport M, Maxwell CJ



**THE COCHRANE
COLLABORATION®**

Diagnostic Test Accuracy of Depression

Screening Tools for Diagnosing DpD

- Canadian Institutes of Health Research Knowledge Synthesis Grant (2015 – 2016)
- Objectives:
 - 1.) Complete a systematic review and meta-analysis of the accuracy of depression ratings scales for the diagnosis of depression in dementia (DpD);
 - 2.) Examine factors that may impact on the accuracy of depression rating scales that are used to diagnose depression; and,
 - 3.) Create knowledge tools to assist clinicians with diagnosing DpD in routine clinical settings.



DpD DTA Review Methods

- Cochrane Review supported through Cochrane Dementia and Cognitive Improvement Group Electronic database search for relevant articles through Cochrane
- Inclusion Criteria:
 - Validated criteria for dementia (e.g. DSM-IV, NINDS-ADRDA)
 - Validated reference standard for MDD (e.g. DSM, DpD criteria)
 - Index test including standard depression rating scales (e.g. HRSD) or scales specific for DpD



DpD DTA Review Methods

- QUADAS-2 assessment for quality of included studies
- Data Extraction:
 - Age, gender, severity of cognitive impairment, type of dementia, residence of participants, criteria and type of dementia, reference standard and index test for DpD
 - TP, TN, FP, FN recorded in 2 X 2 tables for each tool at reported cut-points
- Meta-analysis:
 - Pooled sensitivity and specificity
 - Hierarchical summary ROC for multiple cut-points
 - Assess relative accuracy of scales using regression



Knowledge Translation

- Cochrane Systematic Review
 - Protocol under review, complete review anticipated March 2016
- Creation of DpD online probability calculator



Guidelines

Alexopolous, <i>Postgrad Med</i> , 2005	Herrmann, <i>CMAJ</i> , 2008
AAGP, <i>Am J Geriatr Psychiatry</i> , 2006	NICE-SICE, <i>Dementia Guideline</i> , 2007
APA, 2007 (online)	Royal Australian and New Zealand College of General Practitioners, 2006
Mulsant et al, <i>J Nutr Health Aging</i> , 2006	Royal Australian and New Zealand College of Psychiatrists, 2009
British Columbia Medical Association, 2008	Royal College of Psychiatrists, 2005
<i>CCSMH, Assessment and Treatment of Mental Health Issues in LTC, 2006</i>	Salzman et al., <i>J Clin Psychiatry</i> , 2008
Dettmore, <i>Geriatric Nursing</i> , 2009	Scottish Intercollegiate Guidelines Network, 2006
Fletcher, <i>Evidence-Based Geriatric Nursing</i> , 2008	





Resources

- Canadian Coalition for Seniors' Mental Health
 - www.ccsmh.ca
- International Psychogeriatrics Association
BPSD Guides
 - http://www.ipa-online.net/ipaonlinev4/main/programs/task/task_BPSPD.html



Local Resources

- Alzheimer Society
- Geriatric Psychiatry Programs
 - Providence Care
- Geriatric Medicine Programs
 - Providence Care



Acknowledgments

- Co-Investigators
 - Dr. Nathan Herrmann
 - Dr. Krista Lanctot
 - Dr. Terry Quinn
 - Dr. Yemisi Takwoingi
 - Dr. Colleen Maxwell
 - Dr. Sudeep Gill
 - Dr. Paula Rochon
- Knowledge Users:
 - CCSMH (Bonnie Schroeder)
 - CAGP (Mark Rapoport)
 - Dr. Ken Le Clair and Jillian Dahm-McConnell (brainXchange)
- Funding:
 - CIHR Knowledge Synthesis Grant
 - CIHR CCNA (Team 11: Prevention and Treatment of NPS)
- Cochrane Collaboration
 - Dr. Rupert McShane (Oxford)
 - Sue Marcus (CDCIG)



Conclusions

- Depressive symptoms and MDD are common among older adults with dementia
- Nonpharmacological interventions should be considered first-line treatments for DpD
- Evidence for antidepressants is still developing
- Several screening tools may be helpful for identifying DpD but further information required to optimize in routine practice

Thank You



Dr. Dallas Seitz

- Email: seitzd@providencecare.ca

Dr. Julia Kirkham

- Email: kirkhamj@providencecare.ca



Survey

- Please take a few minutes to complete a short survey to help us better understand what tools would be helpful in identifying DpD:
- <https://www.surveymonkey.com/r/3QZ8WK7>